EGFR and neoplasm: Overall, these data provide evidence that OAd5NULL-A20 CD3/CD16-BICA actively increase T cell and NK cell anti-tumor activity, resulting in enhanced cell death in αvβ6/EGFR/MICA-positive PDAC models, suggesting their therapeutic benefit in a wide range of solid tumors with the same phenotypic profile.